ARTICLE | Emerging Company Profile
Visionary: Sights on drug design
Visionary using structure-based design to discover small molecules
May 14, 2012 7:00 AM UTC
Visionary Pharmaceuticals Inc. believes a large library and computational technology that accounts for conformational changes will allow it to design small molecules that have more drug-like properties than those discovered by conventional high throughput screening.
The company initially is focused on RAR-related orphan receptor C (RORC; RORgamma) and selectins. Both targets are related to T helper type 17 (Th17) cells, a class of lymphocytes implicated in autoimmune and inflammatory diseases...